Literature DB >> 17435179

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

John H Sampson1, Raghu Raghavan, Martin L Brady, James M Provenzale, James E Herndon, David Croteau, Allan H Friedman, David A Reardon, R Edward Coleman, Terence Wong, Darell D Bigner, Ira Pastan, María Inmaculada Rodríguez-Ponce, Philipp Tanner, Raj Puri, Christoph Pedain.   

Abstract

Convection-enhanced delivery (CED) is a novel drug delivery technique that uses positive infusion pressure to deliver therapeutic agents directly into the interstitial spaces of the brain. Despite the promise of CED, clinical trials have demonstrated that target-tissue anatomy and patient-specific physiology play a major role in drug distribution using this technique. In this study, we retrospectively tested the ability of a software algorithm using MR diffusion tensor imaging to predict patient-specific drug distributions by CED. A tumor-targeted cytotoxin, cintredekin besudotox (interleukin 13-PE38QQR), was coinfused with iodine 123-labeled human serum albumin (123I-HSA), in patients with recurrent malignant gliomas. The spatial distribution of 123I-HSA was then compared to a drug distribution simulation provided by the software algorithm. The algorithm had a high sensitivity (71.4%) and specificity (100%) for identifying the high proportion (7 of 14) of catheter trajectories that failed to deliver drug into the desired anatomical region (p = 0.021). This usually occurred when catheter trajectories crossed deep sulci, resulting in leak of the infusate into the subarachnoid cerebrospinal fluid space. The mean concordance of the volume of distribution at the 50% isodose level between the actual 123I-HSA distribution and simulation was 65.75% (95% confidence interval [CI], 52.0%-79.5%), and the mean maximal inplane deviation was less than 8.5 mm (95% CI, 4.0-13.0 mm). The use of this simulation algorithm was considered clinically useful in 84.6% of catheters. Routine use of this algorithm, and its further developments, should improve prospective selection of catheter trajectories, and thereby improve the efficacy of drugs delivered by this promising technique.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435179      PMCID: PMC1907410          DOI: 10.1215/15228517-2007-007

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  44 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

2.  Intraparenchymal drug delivery via positive-pressure infusion: experimental and modeling studies of poroelasticity in brain phantom gels.

Authors:  Zhi-Jian Chen; William C Broaddus; Raju R Viswanathan; Raghu Raghavan; George T Gillies
Journal:  IEEE Trans Biomed Eng       Date:  2002-02       Impact factor: 4.538

3.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

4.  Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.

Authors:  A B Heimberger; G E Archer; R E McLendon; C Hulette; A H Friedman; H S Friedman; D D Bigner; J H Sampson
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

5.  Distribution of AAV-TK following intracranial convection-enhanced delivery into rats.

Authors:  J Cunningham; Y Oiwa; D Nagy; G Podsakoff; P Colosi; K S Bankiewicz
Journal:  Cell Transplant       Date:  2000 Sep-Oct       Impact factor: 4.064

6.  Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.

Authors:  D R Groothuis; H Benalcazar; C V Allen; R M Wise; C Dills; C Dobrescu; V Rothholtz; R M Levy
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

7.  Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

Authors:  J F Hamilton; P F Morrison; M Y Chen; J Harvey-White; R S Pernaute; H Phillips; E Oldfield; K S Bankiewicz
Journal:  Exp Neurol       Date:  2001-03       Impact factor: 5.330

8.  Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies.

Authors:  S Kunwar
Journal:  Acta Neurochir Suppl       Date:  2003

9.  Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.

Authors:  F W Weber; F Floeth; A Asher; R Bucholz; M Berger; M Prados; S Chang; J Bruce; W Hall; N G Rainov; M Westphal; R E Warnick; R W Rand; F Rommell; H Pan; V N Hingorani; R K Puri
Journal:  Acta Neurochir Suppl       Date:  2003

10.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

Authors:  Friedrich Weber; Anthony Asher; Richard Bucholz; Mitchel Berger; Michael Prados; Susan Chang; Jeffrey Bruce; Walter Hall; Nikolai G Rainov; Manfred Westphal; Ronald E Warnick; Robert W Rand; Frank Floeth; Frank Rommel; Henry Pan; Vijay N Hingorani; Raj K Puri
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

View more
  50 in total

1.  Analysis of a simulation algorithm for direct brain drug delivery.

Authors:  Kathryn Hammond Rosenbluth; Jan Felix Eschermann; Gabriele Mittermeyer; Rowena Thomson; Stephan Mittermeyer; Krystof S Bankiewicz
Journal:  Neuroimage       Date:  2011-09-14       Impact factor: 6.556

2.  Current status of intratumoral therapy for glioblastoma.

Authors:  Ankit I Mehta; Andreas Linninger; Maciej S Lesniak; Herbert H Engelhard
Journal:  J Neurooncol       Date:  2015-08-02       Impact factor: 4.130

3.  Voxelized Model of Brain Infusion That Accounts for Small Feature Fissures: Comparison With Magnetic Resonance Tracer Studies.

Authors:  Wei Dai; Garrett W Astary; Aditya K Kasinadhuni; Paul R Carney; Thomas H Mareci; Malisa Sarntinoranont
Journal:  J Biomech Eng       Date:  2016-05       Impact factor: 2.097

4.  Voxelized computational model for convection-enhanced delivery in the rat ventral hippocampus: comparison with in vivo MR experimental studies.

Authors:  Jung Hwan Kim; Garrett W Astary; Svetlana Kantorovich; Thomas H Mareci; Paul R Carney; Malisa Sarntinoranont
Journal:  Ann Biomed Eng       Date:  2012-04-25       Impact factor: 3.934

5.  Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.

Authors:  Y Mardor; D Last; D Daniels; R Shneor; S E Maier; D Nass; Z Ram
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

6.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

Review 7.  Convection-Enhanced Delivery.

Authors:  A M Mehta; A M Sonabend; J N Bruce
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 8.  Convection-enhanced drug delivery for glioblastoma: a review.

Authors:  Randy S D'Amico; Manish K Aghi; Michael A Vogelbaum; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 9.  Convection-enhanced delivery for the treatment of brain tumors.

Authors:  Waldemar Debinski; Stephen B Tatter
Journal:  Expert Rev Neurother       Date:  2009-10       Impact factor: 4.618

10.  Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.

Authors:  Amy Y Grahn; Krystof S Bankiewicz; Millicent Dugich-Djordjevic; John R Bringas; Piotr Hadaczek; Greg A Johnson; Simon Eastman; Matthias Luz
Journal:  J Neurooncol       Date:  2009-05-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.